One of two federal lawsuits pursued by West Virginia and other states alleging that a number of generic drug makers engaged in a scheme to fix prices and allot market share took a step forward last week.
The judge denied the defendants’ joint motion to dismiss plaintiffs’ claims that the drug makers engaged in an overarching conspiracy, and allowed the plaintiffs to move forward to establish those claims.
Curtis Johnson, spokesman for Attorney General Patrick Morrisey, commented, “We believe the order is a big win for the states and private plaintiffs. We believe it has the potential to be a significant factor in moving the cases forward.”
Both suits are in the US District Court for the Eastern District of Pennsylvania before Judge Cynthia Rufe. Both allege that the defendant drug firms colluded to fix and raise prices, and to divvy up market share in order to avoid competition and maintain agreeable, inflated price.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI